C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019

Publisher Name :
Date: 21-May-2019
No. of pages: 125

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019

Summary

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 3, 1, 11 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Report covers products from therapy areas Oncology, Cardiovascular, Genetic Disorders, Hematological Disorders, Immunology, Central Nervous System, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Male Health, Ophthalmology, Respiratory and Undisclosed which include indications Multiple Myeloma (Kahler Disease), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Melanoma, Non-Hodgkin Lymphoma, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Neuroblastoma, Prostate Cancer, Solid Tumor, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Critical Limb Ischemia, Epithelial Ovarian Cancer, Erectile Dysfunction, Gastric Cancer, Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Kidney Fibrosis, Liver Cancer, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Myelodysplastic Syndrome, Myocardial Infarction, Neutropenia, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Immune Deficiency (PID), Recurrent Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Stroke, Thrombocytopenia, Unspecified, Vasomotor Symptoms (Non-Menopausal), Wet (Neovascular / Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

The latest report C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

- The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects

- The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H1 2019

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development
AdAlta Ltd
Ambrx Inc
Biokine Therapeutics Ltd
BioLineRx Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
FairJourney Biologics SA
GlycoMimetics Inc
Pfizer Inc
Polyphor AG
Tactiva Therapeutics LLC
TaiGen Biotechnology Co Ltd
Upsher-Smith Laboratories Inc
X4 Pharmaceuticals Inc
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles
AD-214 - Drug Profile
AM-3114 - Drug Profile
balixafortide - Drug Profile
BKT-300 - Drug Profile
BL-8040 - Drug Profile
burixafor - Drug Profile
GMI-1359 - Drug Profile
HPH-112 - Drug Profile
hz-515H7 - Drug Profile
LY-2510924 - Drug Profile
mavorixafor - Drug Profile
Monoclonal Antibodies to Antagonize CXCR4 for Unspecified Indication - Drug Profile
Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile
Oncolytic Virus to Antagonize CXCR4 for Oncology - Drug Profile
PF-06747143 - Drug Profile
POL-5551 - Drug Profile
Protein to Agonize CXCR4 for Inflammation - Drug Profile
PTX-9908 - Drug Profile
Q-122 - Drug Profile
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile
Small Molecule to Antagonize CXCR4 for Oncology - Drug Profile
ulocuplumab - Drug Profile
USL-311 - Drug Profile
X-4P002 - Drug Profile
X-4P003 - Drug Profile
X4-136 - Drug Profile
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AdAlta Ltd, H1 2019
Pipeline by Ambrx Inc, H1 2019
Pipeline by Biokine Therapeutics Ltd, H1 2019
Pipeline by BioLineRx Ltd, H1 2019
Pipeline by Bristol-Myers Squibb Co, H1 2019
Pipeline by Eli Lilly and Co, H1 2019
Pipeline by FairJourney Biologics SA, H1 2019
Pipeline by GlycoMimetics Inc, H1 2019
Pipeline by Harmonic Pharma, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by Polyphor AG, H1 2019
Pipeline by Que Oncology Inc, H1 2019
Pipeline by Tactiva Therapeutics LLC, H1 2019
Pipeline by TaiGen Biotechnology Co Ltd, H1 2019
Pipeline by Upsher-Smith Laboratories Inc, H1 2019
Pipeline by X4 Pharmaceuticals Inc, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019

List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
  • Global Methoxy Polyethylene Glycol Reagent Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Jul-2019        Price: US 3480 Onwards        Pages: 107
    Scope of the Report: The worldwide market for Methoxy Polyethylene Glycol Reagent is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Methoxy Polyethylene Glycol Reagent in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based o......
  • Global Legalized Cannabis Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Jul-2019        Price: US 3480 Onwards        Pages: 102
    Scope of the Report: The worldwide market for Legalized Cannabis is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Legalized Cannabis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and......
  • Global (United States, European Union and China) Clindamycin phosphate Injection Market Research Report 2019-2025
    Published: 22-Jul-2019        Price: US 3280 Onwards        Pages: 111
    Clindamycin Injection, a water soluble ester of clindamycin and phosphoric acid, is a sterile solution for intramuscular or intravenous use. In 2019, the market size of Clindamycin phosphate Injection is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered ......
  • Global (United States, European Union and China) Antigout Drug Market Research Report 2019-2025
    Published: 22-Jul-2019        Price: US 3280 Onwards        Pages: 111
    Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and swollen joint. Pain typically comes on rapidly in less than twelve hours.The joint at the base of the big toe is affected in about half of cases.It may also result in tophi, kidney stones, or urate nephropathy. In 2019, the market size of Antigout Drug is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued......
  • Global Microbial Sealant Market Insights, Forecast to 2025
    Published: 22-Jul-2019        Price: US 3900 Onwards        Pages: 114
    Microbial Sealant is a microbial barrier designed to reduce the risk of surgical site contamination by skin flora. It forms a protective layer that locks skin flora pathogens in place The global Microbial Sealant market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Microbial Sealant market based on company, product type, end us......
  • Global Fosfomycin Sodium Market Insights, Forecast to 2025
    Published: 22-Jul-2019        Price: US 3900 Onwards        Pages: 113
    The global Fosfomycin Sodium market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Fosfomycin Sodium market based on company, product type, end user and key regions. This report studies the global market size of Fosfomycin Sodium in key regions like North America, Europe, China and Japan, focuses on the consumption of Fo......
  • Global Anaplastic Lymphoma Kinase Inhibitors Market Insights, Forecast to 2025
    Published: 22-Jul-2019        Price: US 3900 Onwards        Pages: 112
    ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[ The global Anaplastic Lymphoma Kinase Inhibitors market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Anaplastic Lymphoma Kinase Inhibitors market based on company, product t......
  • Global Pancreatic and Bile Duct Cancer Drug Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 22-Jul-2019        Price: US 3480 Onwards        Pages: 135
    It is a drug for treating pancreatic cancer with bile duct cancer. Scope of the Report: Pancreatic cancer is a disease in which malignant (cancer) cells are found in pancreatic tissue. The pancreas is a large gland located in the abdominal cavity and is responsible for the secretion of digestive juice and insulin. Symptoms and signs include upper abdominal pain, yellowish skin and white eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Susce......
  • Global Rheumatic Disorders Drug Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    Published: 22-Jul-2019        Price: US 3480 Onwards        Pages: 107
    Treatment of drugs for regulating rheumatic diseases Scope of the Report: Rheumatic diseases are a series of diseases characterized by chronic pain. Some of the most common diseases are osteoarthritis (OA) and rheumatoid arthritis (RA), and most rheumatic diseases use basically universal pain control drugs. Treatment is ongoing and there are no treatments for any of the key indications, so there is a need to develop better disease modulating drugs. The global Rheumat......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs